LGM Pharma Blog N-Zyme Biomedical and LGM Pharma are Developing the World’s First Pepsin Inhibitor for Reflux Disease

N-Zyme Biomedical and LGM Pharma are Developing the World’s First Pepsin Inhibitor for Reflux Disease N-Zyme Biomedical, a pharmaceutical company seeking to provide much-needed treatments for patients that suffer from laryngopharyngeal reflux (LPR) and gastroesophageal reflux disease (GERD), and LGM Pharma, a leading provider of tailored Active Pharmaceutical Ingredients (APIs) and contract development and manufacturing […]